 Optinose Inc NASDAQ: OPTN announced the statistically significant benefits of XHANCE in the ReOpen2 trial for the symptoms co-primary endpoint and the CT scan co-primary endpoint. Significant improvement was seen in patients with chronic sinusitis who did not have nasal. 